Compare BMEZ & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMEZ | KOD |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.9M | 795.5M |
| IPO Year | N/A | 2018 |
| Metric | BMEZ | KOD |
|---|---|---|
| Price | $15.24 | $29.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 391.3K | ★ 929.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.93 | $1.92 |
| 52 Week High | $16.95 | $31.18 |
| Indicator | BMEZ | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 67.09 |
| Support Level | $14.92 | $25.44 |
| Resistance Level | $15.28 | $31.18 |
| Average True Range (ATR) | 0.19 | 2.23 |
| MACD | -0.01 | 0.38 |
| Stochastic Oscillator | 51.30 | 86.73 |
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.